亚太药业(002370.SZ):控股股东及其一致行动人所持2000万股司法拍卖流拍
格隆汇 11 月 3日丨亚太药业(002370.SZ)公布,公司控股股东浙江亚太集团有限公司(以下简称“亚太集团”)及其子公司绍兴柯桥亚太房地产有限公司(以下简称“亚太房地产”)、陈尧根、钟婉珍因与上海浦东发展银行股份有限公司绍兴柯桥支行金融借款合同纠纷一案,浙江省绍兴市中级人民法院于2020年11月2日10时至2020年11月3日10时止(延时的除外)在浙江省绍兴市中级人民法院淘宝网司法拍卖网络平台上对亚太集团持有的本公司400万股股份、亚太房地产持有的本公司1600万股股份进行第二次公开拍卖,根据淘宝网司法拍卖网络平台页面显示的拍卖结果,本次拍卖已流拍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.